Stéphane Bancel, CEO of Moderna

Mod­er­na re­fused to dis­close mR­NA vac­cine tech­nol­o­gy to Chi­na — re­port

Mod­er­na has been pro­tec­tive of the in­tel­lec­tu­al prop­er­ty sur­round­ing its vac­cine, in­clud­ing be­ing will­ing to go to court and ac­cus­ing oth­er com­pa­nies of patent in­fringe­ment. Now the most re­cent up­date puts a mag­ni­fy­ing glass on Mod­er­na’s deal­ings with Chi­na.

Per a re­port from the Fi­nan­cial Times over the week­end, Chi­na asked Mod­er­na to hand over the in­tel­lec­tu­al prop­er­ty be­hind its megablock­buster vac­cine known as Spike­vax. Cit­ing peo­ple “fa­mil­iar with the mat­ter,” the re­port notes that the mR­NA biotech was in ne­go­ti­a­tions with Chi­na in 2020 and 2021 to sell its prod­uct in the world’s most pop­u­lous coun­try.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.